

## News Release

### ***Suven to present at 11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) during OCTOBER 24-27, 2018 - BARCELONA, SPAIN***

**HYDERABAD, INDIA (Oct 23, 2018)** – Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer's Disease at **11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD)** during OCTOBER 24-27, 2018 at BARCELONA, SPAIN

SUVN-502 is a promising pure, 5-HT<sub>6</sub> receptor antagonist in development for the treatment of moderate Alzheimer's Disease, a novel triple combination treatment approach.

This trial evaluates the efficacy and safety of SUVN-502 added to background stable donepezil and memantine, a triple therapy in subjects with moderate AD dementia.

At CTAD, Suven is presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer's Disease.

Top-line efficacy results from this study are expected during August/September of 2019

#### **About Suven Life Sciences**

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010, Phase 1 commenced SUVN-911 and Phase 1 ready SUVN-I6107.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*